<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre=": bold;} span.year {font-family : courier ; font-style : italic;}" exact="Heart" post="LungHeart LungHeart &amp;amp; Lung0147-95631527-3288Published by Elsevier Inc. pmcid: 7500907S0147-9563(20)30381-2"/>
 <result pre="aspects of drug therapy in patients with moderate to severe" exact="infection" post="GhasemiyehParisaabMohammadi-SamaniSolimanbcâ�Ž[a], [b], [c], â�ŽCorresponding author at: School of Pharmacy,"/>
 <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
 <result pre="in COVID-19 patients with underlying diseases, especially cardiac, liver and" exact="kidney diseases." post="â€¢Challenges in COVID-19 management based on pharmacokinetic and pharmacodynamics"/>
 <result pre="with COVID-19 had clinical presentations of dry cough, fever, dyspnea," exact="chest" post="pain, fatigue and malaise, pneumonia, and bilateral infiltration in"/>
 <result pre="cough, fever, dyspnea, chest pain, fatigue and malaise, pneumonia, and" exact="bilateral" post="infiltration in chest CT. Soon COVID-19 was spread around"/>
 <result pre="chest pain, fatigue and malaise, pneumonia, and bilateral infiltration in" exact="chest" post="CT. Soon COVID-19 was spread around the world and"/>
 <result pre="predisposing diseases are highly prone to COVID-19 and manifesting severe" exact="infection" post="especially with organ function damage such as acute respiratory"/>
 <result pre="manifesting severe infection especially with organ function damage such as" exact="acute" post="respiratory distress syndrome, acute kidney injury, septic shock, ventilator-associated"/>
 <result pre="severe infection especially with organ function damage such as acute" exact="respiratory" post="distress syndrome, acute kidney injury, septic shock, ventilator-associated pneumonia,"/>
 <result pre="with organ function damage such as acute respiratory distress syndrome," exact="acute" post="kidney injury, septic shock, ventilator-associated pneumonia, and death. Till"/>
 <result pre="organ function damage such as acute respiratory distress syndrome, acute" exact="kidney injury," post="septic shock, ventilator-associated pneumonia, and death. Till now many"/>
 <result pre="damage such as acute respiratory distress syndrome, acute kidney injury," exact="septic shock," post="ventilator-associated pneumonia, and death. Till now many drugs have"/>
 <result pre="as acute respiratory distress syndrome, acute kidney injury, septic shock," exact="ventilator-associated pneumonia," post="and death. Till now many drugs have been considered"/>
 <result pre="discussed in detail. Also, challenges in the pharmacotherapy of COVID-19" exact="pneumonia" post="in patients with the underlying disease have been considered"/>
 <result pre="the pharmacotherapy of COVID-19 pneumonia in patients with the underlying" exact="disease" post="have been considered based on pharmacokinetic and pharmacodynamic aspects"/>
 <result pre="SARS-CoV-2 COVID-19 Pharmacotherapy Challenges Pharmacokinetic Underlying diseases New corona virus" exact="disease" post="(COVID-19) Coronaviruses are large viruses that are enveloped, non-segmented,"/>
 <result pre="human coronaviruses (HCoVs)1,2 In late December 2019, new cases of" exact="pneumonia" post="caused by a new coronavirus (2019-nCoV), new human-infecting Betacoronavirus,3"/>
 <result pre="symptoms of these patients were dry coughs, fever, dyspnea, and" exact="bilateral" post="infiltration in chest CT. All these patients were associated"/>
 <result pre="patients were dry coughs, fever, dyspnea, and bilateral infiltration in" exact="chest" post="CT. All these patients were associated with Wuhan's Huanan"/>
 <result pre="throat of these patients.4 This new coronavirus was subsequently named" exact="Severe" post="Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Soon this disease,"/>
 <result pre="of these patients.4 This new coronavirus was subsequently named Severe" exact="Acute" post="Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Soon this disease, which"/>
 <result pre="these patients.4 This new coronavirus was subsequently named Severe Acute" exact="Respiratory" post="Syndrome Coronavirus 2 (SARS-CoV-2). Soon this disease, which called"/>
 <result pre="patients.4 This new coronavirus was subsequently named Severe Acute Respiratory" exact="Syndrome" post="Coronavirus 2 (SARS-CoV-2). Soon this disease, which called coronavirus"/>
 <result pre="Syndrome Coronavirus 2 (SARS-CoV-2). Soon this disease, which called coronavirus" exact="disease" post="2019 (COVID-19) by World Health Organization (WHO), promptly spreads"/>
 <result pre="16.5 million cases have been diagnosed with COVID-19 and this" exact="disease" post="became a pandemic. On the late January 2020 COVID-19"/>
 <result pre="male sex, approximately 25% of infected patients involved with severe" exact="disease" post="were required to intensive care unit services and 10%"/>
 <result pre="critical situation, and rest of the patients showed few symptoms," exact="unspecified" post="symptoms or were completely asymptomatic.7 According to recently published"/>
 <result pre="reported include sore throat, headache, confusion, rhinorrhea, sneezing, ageusia, anosmia," exact="chest" post="pain, hypoxemia, pneumonia, hemoptysis, acute cardiac injury, neurologic complications,8,9"/>
 <result pre="confusion, rhinorrhea, sneezing, ageusia, anosmia, chest pain, hypoxemia, pneumonia, hemoptysis," exact="acute" post="cardiac injury, neurologic complications,8,9 and gastrointestinal presentations such as"/>
 <result pre="injury, neurologic complications,8,9 and gastrointestinal presentations such as nausea, vomiting," exact="diarrhea" post="and abdominal pain.3,10, 11, 12 Patients with underlying diseases"/>
 <result pre="with underlying diseases are highly prone to present with severe" exact="infection" post="especially with organ function damage such as acute respiratory"/>
 <result pre="with severe infection especially with organ function damage such as" exact="acute" post="respiratory distress syndrome (ARDS), acute kidney injury (AKI), septic"/>
 <result pre="severe infection especially with organ function damage such as acute" exact="respiratory" post="distress syndrome (ARDS), acute kidney injury (AKI), septic shock,"/>
 <result pre="especially with organ function damage such as acute respiratory distress" exact="syndrome" post="(ARDS), acute kidney injury (AKI), septic shock, and ventilator-associated"/>
 <result pre="organ function damage such as acute respiratory distress syndrome (ARDS)," exact="acute" post="kidney injury (AKI), septic shock, and ventilator-associated pneumonia (VAP).10,13"/>
 <result pre="function damage such as acute respiratory distress syndrome (ARDS), acute" exact="kidney injury" post="(AKI), septic shock, and ventilator-associated pneumonia (VAP).10,13 Severe COVID-19"/>
 <result pre="as acute respiratory distress syndrome (ARDS), acute kidney injury (AKI)," exact="septic shock," post="and ventilator-associated pneumonia (VAP).10,13 Severe COVID-19 could cause death"/>
 <result pre="distress syndrome (ARDS), acute kidney injury (AKI), septic shock, and" exact="ventilator-associated pneumonia" post="(VAP).10,13 Severe COVID-19 could cause death due to huge"/>
 <result pre="syndrome (ARDS), acute kidney injury (AKI), septic shock, and ventilator-associated" exact="pneumonia" post="(VAP).10,13 Severe COVID-19 could cause death due to huge"/>
 <result pre="acute kidney injury (AKI), septic shock, and ventilator-associated pneumonia (VAP).10,13" exact="Severe" post="COVID-19 could cause death due to huge alveolar damage"/>
 <result pre="cause death due to huge alveolar damage and highly progressive" exact="respiratory" post="failure.14 Transmission and spread COVID-19 particles could spread through"/>
 <result pre="failure.14 Transmission and spread COVID-19 particles could spread through the" exact="respiratory" post="mucosa10 and fecal-oral route.11 The nucleic acid of the"/>
 <result pre="acid of the virus was detected in stool, saliva, and" exact="respiratory" post="specimens.11 This virus could be transmitted between humans during"/>
 <result pre="of the infected patients who are capable to spread the" exact="respiratory" post="droplets. Then these respiratory droplets could settle in oral"/>
 <result pre="who are capable to spread the respiratory droplets. Then these" exact="respiratory" post="droplets could settle in oral mucosa and lung of"/>
 <result pre="respiratory droplets. Then these respiratory droplets could settle in oral" exact="mucosa" post="and lung of the people who inhaled the contaminated"/>
 <result pre="regular surface disinfecting is required, social distancing from people with" exact="respiratory" post="symptoms is essential, sneezing or coughing should be done"/>
 <result pre="is essential, sneezing or coughing should be done into the" exact="elbow" post="or soft tissue if available.16 COVID-19 diagnosis Based on"/>
 <result pre="especially lymphocytes, the clinical outcome of such events would be" exact="respiratory" post="distress syndrome, septic shock and finally end-organ damage.10 COVID-19"/>
 <result pre="clinical outcome of such events would be respiratory distress syndrome," exact="septic shock" post="and finally end-organ damage.10 COVID-19 could also affect the"/>
 <result pre="showed moderate micro-vesicular steatosis and also a mild portal and" exact="lobular" post="activity which could be a result of direct SARS-CoV-2"/>
 <result pre="the number of involved lung segments was significantly higher in" exact="symptomatic" post="patients group in comparison to asymptomatic ones. CT findings"/>
 <result pre="CT findings revealed that affected COVID-19 patients could present as" exact="bilateral" post="lung involvement, peripheral distribution, or diffuse distribution. The most"/>
 <result pre="that affected COVID-19 patients could present as bilateral lung involvement," exact="peripheral" post="distribution, or diffuse distribution. The most common presentation in"/>
 <result pre="patients could present as bilateral lung involvement, peripheral distribution, or" exact="diffuse" post="distribution. The most common presentation in chest CT was"/>
 <result pre="peripheral distribution, or diffuse distribution. The most common presentation in" exact="chest" post="CT was ground-glass opacity pattern, consolidation, and ill-defined margins.18,19"/>
 <result pre="studied in relief of COVID-19 clinical presentation. Table 1 Drug" exact="Adult" post="Dosage Pediatric Dosage Route of Administration Chloroquine phosphate 500"/>
 <result pre="relief of COVID-19 clinical presentation. Table 1 Drug Adult Dosage" exact="Pediatric" post="Dosage Route of Administration Chloroquine phosphate 500 mg (300"/>
 <result pre="second day â€¢BW1 of â‰¥ 40 kg: similar to the" exact="adult" post="dosage29. IV infusion Tocilizumab 8 mg/kg every 4 weeks"/>
 <result pre="management Drugs/Approaches Clinical considerations FDA approved32 1. Remdesivir2. Dexamethasone3. Aviptadil" exact="Severe" post="cases of COVID-19 and COVID-19 induced ARDS Under clinical"/>
 <result pre="in COVID-19 treatment. Hydroxychloroquine is a common drug in many" exact="autoimmune" post="disorders such as lupus and rheumatoid arthritis, also it"/>
 <result pre="is a common drug in many autoimmune disorders such as" exact="lupus" post="and rheumatoid arthritis, also it has a strong immunomodulatory"/>
 <result pre="common drug in many autoimmune disorders such as lupus and" exact="rheumatoid arthritis," post="also it has a strong immunomodulatory effect that can"/>
 <result pre="of 2019-nCoV-induced pneumonia, normalizing patientsâ€™ lung CT scans, shortening the" exact="disease" post="duration and length of hospitalization, and induction of virus-negative"/>
 <result pre="of chloroquine in patients with mild, moderate, or severe COVID-19" exact="pneumonia" post="is 500 mg twice daily. Chloroquine is a safe,"/>
 <result pre="in France. Results revealed that hydroxychloroquine could significantly reduce the" exact="viral" post="load and azithromycin could reinforce its clinical effect, but"/>
 <result pre="administration (case group) was significantly associated with higher incidence of" exact="total" post="adverse effects in comparison to placebo or no treatment"/>
 <result pre="individualized pharmacotherapy. Also, close patient monitoring, especially cardiac, ocular, and" exact="neurotoxicity" post="assessments, are required and strongly recommended during drug administration.46"/>
 <result pre="which are highly affected in COVID-19 pneumonia. Chloroquine could stop" exact="viral infection" post="by enhancing the pH of endosomes which is required"/>
 <result pre="are highly affected in COVID-19 pneumonia. Chloroquine could stop viral" exact="infection" post="by enhancing the pH of endosomes which is required"/>
 <result pre="interfering with their acidification process. Therefore chloroquine could inhibit pH-dependent" exact="viral" post="fusion and replication. Also, it might inhibit viral assembly"/>
 <result pre="inhibit pH-dependent viral fusion and replication. Also, it might inhibit" exact="viral" post="assembly in endoplasmic reticulum-Golgi intermediate like structures.47 Another possible"/>
 <result pre="replication. Also, it might inhibit viral assembly in endoplasmic reticulum-Golgi" exact="intermediate" post="like structures.47 Another possible antiviral mechanism of chloroquine is"/>
 <result pre="the action of hydroxychloroquine. It can suppress the cytokine release" exact="syndrome" post="(CRS), which is a result of immune system over-activation,"/>
 <result pre="Chloroquine/Hydroxychloroquine adverse reactions Chloroquine has different adverse reactions such as" exact="cardiovascular" post="adverse reactions (atrioventricular block, cardiac arrhythmia, QT prolongation, torsades"/>
 <result pre="different adverse reactions such as cardiovascular adverse reactions (atrioventricular block," exact="cardiac arrhythmia," post="QT prolongation, torsades de pointes, etc.), ophthalmic adverse drug"/>
 <result pre="pointes, etc.), ophthalmic adverse drug reactions (blurred vision, corneal opacity," exact="macular degeneration," post="maculopathy and retinopathy [which are depends on cumulative doses"/>
 <result pre="and retinopathy [which are depends on cumulative doses of chloroquine]," exact="nocturnal" post="amblyopia, accommodation disturbances, etc), otic adverse drug reactions (deafness,"/>
 <result pre="nocturnal amblyopia, accommodation disturbances, etc), otic adverse drug reactions (deafness," exact="hearing loss" post="and tinnitus), central nervous system (CNS) adverse reactions (agitation,"/>
 <result pre="etc), otic adverse drug reactions (deafness, hearing loss and tinnitus)," exact="central nervous system" post="(CNS) adverse reactions (agitation, anxiety, confusion, etc.), endocrine and"/>
 <result pre="reactions such as hypoglycemia, hematologic and oncologic (agranulocytosis, aplastic or" exact="hemolytic anemia," post="neutropenia, pancytopenia, etc.), gastrointestinal adverse reactions, hepatic adverse reactions"/>
 <result pre="could induce severe dermatologic side effects such as Stevens Johnson" exact="syndrome" post="(SJS) in a patient with COVID-19.50 Also the results"/>
 <result pre="administration were rash, SJS,toxic epidermal necrolysis (TEN), pruritus, hyperpigmentation, and" exact="hair loss." post="These dermatologic reactions were mostly occurred after cumulative dosages"/>
 <result pre="after cumulative dosages of hydroxychloroquine.51 In overall, since hydroxychloroquine has" exact="lower" post="tissue accumulation potential in comparison with chloroquine, it has"/>
 <result pre="be better choice.38 Chloroquine/Hydroxychloroquine contraindications Contraindications in chloroquine use contains" exact="hypersensitivity" post="to chloroquine (4-aminoquinolone compounds) and the presence of retinal"/>
 <result pre="to chloroquine (4-aminoquinolone compounds) and the presence of retinal or" exact="visual" post="field changes.52 Chloroquine/Hydroxychloroquine pharmacokinetics Chloroquine and hydroxychloroquine can distribute"/>
 <result pre="widely in the whole body after oral administration. Hydroxychloroquine has" exact="incomplete" post="and variable (about 70%) absorption, while chloroquine has rapid"/>
 <result pre="variable (about 70%) absorption, while chloroquine has rapid and almost" exact="complete" post="absorption. Both have moderate plasma protein binding. Both have"/>
 <result pre="a narrow therapeutic index and poisoning could be occurred with" exact="cardiovascular" post="features so it should be used with caution in"/>
 <result pre="it should be used with caution in patients with predisposing" exact="cardiovascular" post="disease.37 Long-term exposure to these drugs could induce cardiomyopathy.38"/>
 <result pre="with hepatic failure but it should be used with caution.52" exact="Kidney" post="diseases There is no dosage adjustments available for chloroquine"/>
 <result pre="is no dosage adjustments available for chloroquine in patients with" exact="renal failure" post="from the manufacture's labeling but according to UpToDate some"/>
 <result pre="required. There is no dosage adjustments available for hydroxychloroquine in" exact="renal failure" post="but it should be used with caution.52 Pregnancy Although"/>
 <result pre="in renal failure but it should be used with caution.52" exact="Pregnancy" post="Although some studies showed a low risk of congenital"/>
 <result pre="caution.52 Pregnancy Although some studies showed a low risk of" exact="congenital" post="abnormalities in patients receiving chloroquine during pregnancy because of"/>
 <result pre="pregnancy because of the lack of a pattern in these" exact="congenital" post="defects, the possible association is unlikely and it seems"/>
 <result pre="would be a better option in pregnant women with COVID-19" exact="infection" post="because of its safety profile during pregnancy.38 Lactation According"/>
 <result pre="of its safety profile during pregnancy.38 Lactation According to the" exact="American" post="Academy of Pediatrics, chloroquine is compatible with breastfeeding. Although"/>
 <result pre="was not considered harmful for nursing infants.53 According to the" exact="American" post="Academy of Pediatrics, hydroxychloroquine is compatible with breastfeeding. Small"/>
 <result pre="and non-enveloped RNA or DNA viruses especially against influenza virus" exact="type A" post="and B, respiratory syncytial virus, SARS-CoV, adenovirus, hepatitis C"/>
 <result pre="DNA viruses especially against influenza virus type A and B," exact="respiratory" post="syncytial virus, SARS-CoV, adenovirus, hepatitis C virus (HCV), etc."/>
 <result pre="virus type A and B, respiratory syncytial virus, SARS-CoV, adenovirus," exact="hepatitis C" post="virus (HCV), etc. Umifenovir was first developed in Russia"/>
 <result pre="western countries. Its possible antiviral mechanism is the inhibition of" exact="viral" post="fusion with targeted membrane and preventing from the viral"/>
 <result pre="of viral fusion with targeted membrane and preventing from the" exact="viral" post="entrance to targeted cells.54 Umifenovir mechanism of action in"/>
 <result pre="a dual pharmacologic action: First is its beneficial effect on" exact="respiratory" post="viruses such as the COVID-19 virus and the second"/>
 <result pre="patented for its beneficial effect in the treatment of severe" exact="acute" post="respiratory distress (SARS) coronavirus-induced atypical pneumonia.55 Results revealed that"/>
 <result pre="for its beneficial effect in the treatment of severe acute" exact="respiratory" post="distress (SARS) coronavirus-induced atypical pneumonia.55 Results revealed that umifenovircan"/>
 <result pre="in the treatment of severe acute respiratory distress (SARS) coronavirus-induced" exact="atypical" post="pneumonia.55 Results revealed that umifenovircan induce direct viricidal effect"/>
 <result pre="promising direct-acting antiviral (DAA) agent. Umifenovircould affect critical stages of" exact="viral" post="life cycles such as cell attachment, cell internalization, viral"/>
 <result pre="of viral life cycles such as cell attachment, cell internalization," exact="viral" post="replication, assembly, and budding so it also would be"/>
 <result pre="potential interaction with both cell membranes and with cellular and" exact="viral" post="lipids and proteins.55 Umifenovir adverse reactions The most important"/>
 <result pre="(Cmax) was achieved after 1 to 1.5 hours. In the" exact="Russian" post="population, it had elimination half-life (t Â½) of 17"/>
 <result pre="be used with caution in patients with predisposing liver diseases." exact="Pregnancy" post="Animal data revealed that umifenovirtherapy couldn't induce embryo-toxic effects"/>
 <result pre="intracellular GTP would be diminished which inhibits RNA replication of" exact="viral" post="genomes, so viral growth might be stopped. Another possible"/>
 <result pre="be diminished which inhibits RNA replication of viral genomes, so" exact="viral" post="growth might be stopped. Another possible antiviral activity of"/>
 <result pre="and therefore inhibition of RNA fragmentsâ€™ initiation and elongation, so" exact="viral" post="protein synthesis could be inhibited. Ribavirin adverse reactions The"/>
 <result pre="and hemolytic anemia), hepatic adverse reactions (elevated serum bilirubin level)," exact="respiratory" post="adverse reactions (flu-like symptoms, upper respiratory tract infection, dyspnea,"/>
 <result pre="reactions (elevated serum bilirubin level), respiratory adverse reactions (flu-like symptoms," exact="upper respiratory tract infection," post="dyspnea, cough, pharyngitis, sinusitis, etc.), weakness, muscle pain, etc."/>
 <result pre="(elevated serum bilirubin level), respiratory adverse reactions (flu-like symptoms, upper" exact="respiratory" post="tract infection, dyspnea, cough, pharyngitis, sinusitis, etc.), weakness, muscle"/>
 <result pre="upper respiratory tract infection, dyspnea, cough, pharyngitis, sinusitis, etc.), weakness," exact="muscle" post="pain, etc. The less common adverse reactions are cardiovascular"/>
 <result pre="weakness, muscle pain, etc. The less common adverse reactions are" exact="cardiovascular" post="events such as chest pain and flushing.52 Ribavirin contraindications"/>
 <result pre="The less common adverse reactions are cardiovascular events such as" exact="chest" post="pain and flushing.52 Ribavirin contraindications Ribavirin is contraindicated in"/>
 <result pre="and flushing.52 Ribavirin contraindications Ribavirin is contraindicated in patients with" exact="hypersensitivity" post="to ribavirin, pregnant women and their partner, patients with"/>
 <result pre="to ribavirin, pregnant women and their partner, patients with severe" exact="renal failure," post="patients with severe hepatic failure, and patients with major"/>
 <result pre="failure, patients with severe hepatic failure, and patients with major" exact="hemoglobinopathies" post="such as sickle cell anemia and major thalassemia.52 Ribavirin"/>
 <result pre="severe hepatic failure, and patients with major hemoglobinopathies such as" exact="sickle cell anemia" post="and major thalassemia.52 Ribavirin pharmacokinetics Ribavirin distribution could significantly"/>
 <result pre="failure, and patients with major hemoglobinopathies such as sickle cell" exact="anemia" post="and major thalassemia.52 Ribavirin pharmacokinetics Ribavirin distribution could significantly"/>
 <result pre="normal population is 24 hours but in patients with pre-existing" exact="chronic hepatitis C" post="infection, half-life could be increased to 44 hours. So"/>
 <result pre="population is 24 hours but in patients with pre-existing chronic" exact="hepatitis C" post="infection, half-life could be increased to 44 hours. So"/>
 <result pre="of its renal elimination, dose adjustment in patients with underlying" exact="kidney disease" post="is highly essential. According to the previous pharmacokinetic/pharmacodynamic study,"/>
 <result pre="its renal elimination, dose adjustment in patients with underlying kidney" exact="disease" post="is highly essential. According to the previous pharmacokinetic/pharmacodynamic study,"/>
 <result pre="drug monitoring would be a suitable approach to control ribavirin-induced" exact="anemia" post="[41]. Patients with predisposing diseases and special conditions Cardiovascular"/>
 <result pre="One of the most important side effects of ribavirin is" exact="hemolytic anemia" post="which could worsen cardiac disease in patients with underlying"/>
 <result pre="of the most important side effects of ribavirin is hemolytic" exact="anemia" post="which could worsen cardiac disease in patients with underlying"/>
 <result pre="side effects of ribavirin is hemolytic anemia which could worsen" exact="cardiac disease" post="in patients with underlying cardiac diseases and it could"/>
 <result pre="effects of ribavirin is hemolytic anemia which could worsen cardiac" exact="disease" post="in patients with underlying cardiac diseases and it could"/>
 <result pre="underlying cardiac diseases and it could induce fatal or non-fatal" exact="myocardial infarction" post="in them. So ribavirin should be avoided in patients"/>
 <result pre="in patients with hepatic decompensation (Child-Pugh class B and C)." exact="Kidney" post="diseases Ribavirin dosage adjustment in patients with renal failure"/>
 <result pre="and C). Kidney diseases Ribavirin dosage adjustment in patients with" exact="renal failure" post="highly depends on different formulations which are available. These"/>
 <result pre="200 mg once daily 200 mg once daily 1End stage" exact="renal disease" post="Pregnancy Ribavirin has teratogenic and mutagenic effects. So it"/>
 <result pre="mg once daily 200 mg once daily 1End stage renal" exact="disease" post="Pregnancy Ribavirin has teratogenic and mutagenic effects. So it"/>
 <result pre="once daily 200 mg once daily 1End stage renal disease" exact="Pregnancy" post="Ribavirin has teratogenic and mutagenic effects. So it is"/>
 <result pre="that lopinavir/ritonavir in combination with ribavirin and IFN-Î± could promote" exact="viral" post="clearance and enhance patientsâ€™ survival. The results of a"/>
 <result pre="study was the heterogeneity of the sample population according to" exact="disease" post="severity and duration of the COVID-19 course.61 So further"/>
 <result pre="in patients with COVID-19 could improve clinical symptoms and reduce" exact="viral" post="load. Lopinavir/ritonavir would be a promising agent in high-risk"/>
 <result pre="patients, such as elderly groups and patients with the underlying" exact="disease" post="who are infected with COVID-19.62 Also, lopinavir would be"/>
 <result pre="agents. The potential antiviral mechanism of lopinavir/ritonavir is inhibition of" exact="viral" post="protease, which is a critical enzyme in viral maturation"/>
 <result pre="inhibition of viral protease, which is a critical enzyme in" exact="viral" post="maturation and infectivity. Low dose ritonavir in combination with"/>
 <result pre="gastrointestinal and digestive adverse reactions, hepatic adverse reactions such as" exact="elevated serum" post="ALT level, and upper respiratory tract infections. Other less"/>
 <result pre="hepatic adverse reactions such as elevated serum ALT level, and" exact="upper" post="respiratory tract infections. Other less common adverse reactions contains"/>
 <result pre="adverse reactions such as elevated serum ALT level, and upper" exact="respiratory" post="tract infections. Other less common adverse reactions contains cardiovascular"/>
 <result pre="upper respiratory tract infections. Other less common adverse reactions contains" exact="cardiovascular" post="events such as vasodilation, elevated AST level, hematologic adverse"/>
 <result pre="administer this drug they should consider digestive adverse effects and" exact="hypokalemia" post="in patients with COVID-19 infection.64 Lopinavir/Ritonavir drug interactions Since"/>
 <result pre="Lopinavir/Ritonavir contraindications Lopinavir/ritonaviris contraindicated in patients with a history of" exact="hypersensitivity" post="reactions such as toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome,"/>
 <result pre="in patients with a history of hypersensitivity reactions such as" exact="toxic epidermal necrolysis" post="(TEN), Stevens-Johnson syndrome, angioedema, etc. to lopinavir/ritonavir or its"/>
 <result pre="history of hypersensitivity reactions such as toxic epidermal necrolysis (TEN)," exact="Stevens-Johnson syndrome," post="angioedema, etc. to lopinavir/ritonavir or its components.52 Lopinavir/Ritonavir pharmacokinetics"/>
 <result pre="elimination, no dosage adjustment is required in patients with underlying" exact="kidney disease" post="and it could be administered safely.52 Ritonavir also has"/>
 <result pre="no dosage adjustment is required in patients with underlying kidney" exact="disease" post="and it could be administered safely.52 Ritonavir also has"/>
 <result pre="pharmacokinetic enhancer by inhibition of lopinavir inactivation metabolism through inhibition" exact="of liver" post="and intestinal CYP3A4 and inhibition of P-glycoprotein efflux pump.65"/>
 <result pre="Cardiovascular diseases Lopinavir/ritonavir have major interactions with drugs used in" exact="cardiovascular" post="diseases such as anti-coagulating agents (anti-factor Xa inhibitors), none"/>
 <result pre="close patient monitoring is required in COVID-19 patients with pre-existing" exact="cardiovascular disease" post="who are planned to treat with lopinavir/ritonavir and sometimes"/>
 <result pre="patient monitoring is required in COVID-19 patients with pre-existing cardiovascular" exact="disease" post="who are planned to treat with lopinavir/ritonavir and sometimes"/>
 <result pre="failure, there is no dosage adjustments available but lopinavir has" exact="primary" post="liver metabolism and its AUC will be increase by"/>
 <result pre="about 30 %, so it should be used with caution.52" exact="Kidney" post="diseases There is no dosage adjustments based on renal"/>
 <result pre="adjustments based on renal function according to the manufacture's labeling.52" exact="Pregnancy" post="Results revealed that embryo-fetal risk of lopinavir/ritonavir is low,"/>
 <result pre="Tocilizumab Tocilizumab is an interleukin-6 (IL-6) inhibitor which is a" exact="disease" post="modifying anti-rheumatic agent.67 A small retrospective observational study on"/>
 <result pre="modifying anti-rheumatic agent.67 A small retrospective observational study on COVID-19" exact="pneumonia" post="patients receiving tocilizumab revealed that this drug would have"/>
 <result pre="and enhancing O2 saturation. Tocilizumab mechanisms of action in COVID-19" exact="pneumonia" post="is attributed to the critical role of IL-6 in"/>
 <result pre="the critical role of IL-6 in the hyper-inflammatory state after" exact="infection" post="with COVID-19, so the blockers of IL-6 would be"/>
 <result pre="Since the number of pro-inflammatory cytokines in COVID-19-induced cytokine release" exact="syndrome" post="(CRS), is inversely related to absolute lymphocyte count, so"/>
 <result pre="an IL-6 antagonist, would be a promising agent to enhance" exact="viral" post="clearance and relieve COVID-19 pneumonia complications,68,69 Further clinical trial"/>
 <result pre="a promising agent to enhance viral clearance and relieve COVID-19" exact="pneumonia" post="complications,68,69 Further clinical trial results are required to confirm"/>
 <result pre="cells are highly exhausted. Since an active immune response against" exact="respiratory" post="viruses such as COVID-19 is highly dependent on cytotoxic"/>
 <result pre="dependent on cytotoxic T cellsâ€™ action, so in patients with" exact="total" post="T cell count of fewer than 800 cells/ÂµL, aggressive"/>
 <result pre="is a broad-spectrum antiviral agent that is commonly used in" exact="hepatitis" post="management. After the confirmation of the in vitro efficacy"/>
 <result pre="of IFN-Î± in COVID-19 patients is vapor inhalation with an" exact="adult" post="dosage of 5 million U twice daily.25 Subcutaneous administration"/>
 <result pre="overdosing in children could cause elevated liver enzyme levels, bleeding," exact="acute" post="kidney injury and renal failure, etc. Another concern about"/>
 <result pre="in children could cause elevated liver enzyme levels, bleeding, acute" exact="kidney injury" post="and renal failure, etc. Another concern about the administration"/>
 <result pre="cause elevated liver enzyme levels, bleeding, acute kidney injury and" exact="renal failure," post="etc. Another concern about the administration of IFN-Î± in"/>
 <result pre="is a glycopeptide antibiotic. It is commonly used in Gram-positive" exact="bacterial infections." post="Recent in vitro studies showed that teicoplanin could be"/>
 <result pre="enhancement of the endosomal pH and thereby inhibition of low-pH" exact="viral" post="spike protein cleavage in endosome by Cathepsin L, this"/>
 <result pre="results in avoidance of genomic RNA release and replication of" exact="viral" post="life cycle which would be stopped at early stages."/>
 <result pre="these results, teicoplanin would be a promising alternative in COVID-19" exact="pneumonia" post="treatment but further randomized clinical trials are required to"/>
 <result pre="antiviral activity of azithromycin and also it could prevent severe" exact="viral" post="respiratory tract infections in patients infected with respiratory viruses."/>
 <result pre="activity of azithromycin and also it could prevent severe viral" exact="respiratory" post="tract infections in patients infected with respiratory viruses. A"/>
 <result pre="azithromycin and also it could prevent severe viral respiratory tract" exact="infections" post="in patients infected with respiratory viruses. A recent publication"/>
 <result pre="prevent severe viral respiratory tract infections in patients infected with" exact="respiratory" post="viruses. A recent publication showed that azithromycin in combination"/>
 <result pre="prolongation and Torsades de points.42 especially in patients with underlying" exact="cardiovascular" post="diseases. So, close patient monitoring is required during the"/>
 <result pre="the nascent RNA chain of the virus and causing premature" exact="viral" post="cycle termination, but this stage is a post virus"/>
 <result pre="in adults and children with severe disease. While there is" exact="limited" post="information about the safety and clinical efficacy of remdesivir"/>
 <result pre="February to 12th March 2020, revealed that remdesivir administration in" exact="adult" post="COVID-19 patients with severe disease was not significantly associated"/>
 <result pre="revealed that remdesivir administration in adult COVID-19 patients with severe" exact="disease" post="was not significantly associated with shorter recovery time and"/>
 <result pre="is highly responsive to the lung damage and ARDS during" exact="viral infection." post="Although corticosteroids were used in the management of SARS/MERS-CoV"/>
 <result pre="SARS/MERS-CoV outbreaks, corticosteroids have the disadvantage of increased incidence of" exact="secondary" post="bacterial and fungal infections and also increase the length"/>
 <result pre="outbreaks, corticosteroids have the disadvantage of increased incidence of secondary" exact="bacterial" post="and fungal infections and also increase the length of"/>
 <result pre="the disadvantage of increased incidence of secondary bacterial and fungal" exact="infections" post="and also increase the length of patient's staying in"/>
 <result pre="any significant beneficial effect in patients who did not require" exact="respiratory" post="support.75 There are controversial comments on the usage of"/>
 <result pre="A possible disadvantage of NSAIDs such as Ibuprofen in COVID-19" exact="infection" post="is their potential effects in over-expression of ACE2 and"/>
 <result pre="(a phosphorylated form of favipiravir), which is a substrate for" exact="viral" post="RNA polymerases. By adhesion of favipiravir to viral RNA"/>
 <result pre="substrate for viral RNA polymerases. By adhesion of favipiravir to" exact="viral" post="RNA polymerase, RNA polymerase activity would be inhibited. With"/>
 <result pre="COVID-19 patients. Previous results revealed that convalescent plasma therapy during" exact="viral infection" post="outbreaks, could improve patientsâ€™ survival rate, shorten the duration"/>
 <result pre="patients. Previous results revealed that convalescent plasma therapy during viral" exact="infection" post="outbreaks, could improve patientsâ€™ survival rate, shorten the duration"/>
 <result pre="improve patientsâ€™ survival rate, shorten the duration of hospitalization, reduce" exact="viral" post="load, and reduce the mortality rate. A potential mechanism"/>
 <result pre="could reach its peak state during the first week of" exact="viral infection," post="so convalescent plasma therapy should be done at the"/>
 <result pre="therapy should be done at the early stages of COVID-19" exact="infection" post="to reach its most efficacy. According to the recent"/>
 <result pre="recovered from COVID-19 would be a promising option in COVID-19" exact="infection" post="treatment. This approach has been considered safe with no"/>
 <result pre="supportive care, could improve clinical symptoms (such as fever, cough," exact="chest" post="pain, etc.), improve pulmonary abnormalities on chest CT, and"/>
 <result pre="clinical symptoms (such as fever, cough, chest pain, etc.), improve" exact="pulmonary" post="abnormalities on chest CT, and normalize laboratory data (such"/>
 <result pre="as fever, cough, chest pain, etc.), improve pulmonary abnormalities on" exact="chest" post="CT, and normalize laboratory data (such as C-reactive protein"/>
 <result pre="be a safe method in COVID-19 management which could reduce" exact="viral" post="load. So, convalescent plasma therapy has been suggested as"/>
 <result pre="a well-tolerated and feasible approach in patients with severe COVID-19" exact="pneumonia" post="through neutralizing of viremia.77 Aviptadil Aviptadil is a vasoactive"/>
 <result pre="intestinal polypeptide (VIP) which is administered in Europe to treat" exact="erectile dysfunction." post="According to the results, aviptadil could be highly concentrated"/>
 <result pre="cases of COVID-19 who were on mechanical ventilation.78 Supportive therapy" exact="Vitamin C" post="Ascorbic acid (vitamin C), is an antioxidant agent and"/>
 <result pre="vitamin C would be a promising agent in sepsis and" exact="septic shock" post="management. ARDS could be a life-threatening consequence of sepsis"/>
 <result pre="management. ARDS could be a life-threatening consequence of sepsis or" exact="septic shock." post="High dose vitamin C has dual effects; it can"/>
 <result pre="for immune cells and as an antioxidant agent for lung" exact="epithelial" post="cells. Another possible mechanism of vitamin C is inhibition"/>
 <result pre="immune cells and therefore preserve the innate immunity of alveolar" exact="epithelial" post="cells type II.79 So high dose IV vitamin C"/>
 <result pre="recommended dose of vitamin C in patients with severe COVID-19" exact="pneumonia" post="is 50 mg/kg IV every 6 hours for 4"/>
 <result pre="that vitamin C could have a preventive role in COVID-19" exact="lower" post="respiratory tract infection. So supplementation with a moderate amount"/>
 <result pre="vitamin C could have a preventive role in COVID-19 lower" exact="respiratory" post="tract infection. So supplementation with a moderate amount of"/>
 <result pre="bypass machine which has been used in patients with refractory" exact="respiratory" post="or cardiac failure. In this approach, oxygen would be"/>
 <result pre="multi-organ failure and those with underlying cardiac diseases such as" exact="ischemic heart disease" post="or heart failure, ECMO might be considered as a"/>
 <result pre="failure and those with underlying cardiac diseases such as ischemic" exact="heart" post="disease or heart failure, ECMO might be considered as"/>
 <result pre="and those with underlying cardiac diseases such as ischemic heart" exact="disease" post="or heart failure, ECMO might be considered as a"/>
 <result pre="with underlying cardiac diseases such as ischemic heart disease or" exact="heart" post="failure, ECMO might be considered as a potential option"/>
 <result pre="considered as a potential option especially in patients who develop" exact="cardiac arrhythmia" post="and septic shock during COVID-19 pneumonia.81 Deferoxamine Iron toxicity"/>
 <result pre="as a potential option especially in patients who develop cardiac" exact="arrhythmia" post="and septic shock during COVID-19 pneumonia.81 Deferoxamine Iron toxicity"/>
 <result pre="potential option especially in patients who develop cardiac arrhythmia and" exact="septic shock" post="during COVID-19 pneumonia.81 Deferoxamine Iron toxicity has a multi-stage"/>
 <result pre="liver damage, and cardiomyopathy) would be occur. After that enhancement" exact="of liver" post="aminotransferases would be appear. The adhesion of SARS-CoV-2 protein"/>
 <result pre="toxicity. This iron toxicity leads to alveolar macrophage inflammation and" exact="chest" post="infiltrations. In moderate to severe cases of COVID-19 pneumonia,"/>
 <result pre="In moderate to severe cases of COVID-19 pneumonia, symptoms of" exact="iron overload" post="such as shock, end-organ damage (renal failure, hepatic failure,"/>
 <result pre="damage (renal failure, hepatic failure, and cardiac events), and elevation" exact="of liver" post="aminotransferases would be appeared. It seems that the recruitment"/>
 <result pre="in COVID-19 patients.34,35 Recommended regimens for confirmed COVID-19 based on" exact="disease" post="severity In some European countries, patients with confirmed COVID-19"/>
 <result pre="confirmed COVID-19 could be treated according to the degree of" exact="disease" post="severity through the regimens as listed below: Mild to"/>
 <result pre="severity through the regimens as listed below: Mild to moderate" exact="disease" post="in no risk group Mild to moderate disease refers"/>
 <result pre="to moderate disease in no risk group Mild to moderate" exact="disease" post="refers to the condition that there is no oxygen"/>
 <result pre="not required. They should be managed with supportive care and" exact="symptomatic" post="therapy.82 Mild to moderate disease in the risk group"/>
 <result pre="managed with supportive care and symptomatic therapy.82 Mild to moderate" exact="disease" post="in the risk group This group also categorized as"/>
 <result pre="risk group This group also categorized as mild to moderate" exact="disease" post="but patients have risk factors such as the age"/>
 <result pre="of over 60 years and patients with underlying diseases (ex." exact="liver disease," post="kidney disease, heart disease, diabetes, chronic obstructive pulmonary disease,"/>
 <result pre="60 years and patients with underlying diseases (ex. liver disease," exact="kidney disease," post="heart disease, diabetes, chronic obstructive pulmonary disease, hypertension, etc.)"/>
 <result pre="and patients with underlying diseases (ex. liver disease, kidney disease," exact="heart" post="disease, diabetes, chronic obstructive pulmonary disease, hypertension, etc.) In"/>
 <result pre="underlying diseases (ex. liver disease, kidney disease, heart disease, diabetes," exact="chronic" post="obstructive pulmonary disease, hypertension, etc.) In this group, lopinavir/ritonavir"/>
 <result pre="(ex. liver disease, kidney disease, heart disease, diabetes, chronic obstructive" exact="pulmonary" post="disease, hypertension, etc.) In this group, lopinavir/ritonavir plus chloroquine"/>
 <result pre="of therapy in this group is 5 to 7 days.82" exact="Severe" post="disease COVID-19 could be categorized as a severe disease"/>
 <result pre="therapy in this group is 5 to 7 days.82 Severe" exact="disease" post="COVID-19 could be categorized as a severe disease if"/>
 <result pre="days.82 Severe disease COVID-19 could be categorized as a severe" exact="disease" post="if one or more of the following conditions have"/>
 <result pre="to 20 days which is dependent on the monitoring of" exact="viral" post="excretion.82 Critical disease COVID-19 could be categorized as a"/>
 <result pre="which is dependent on the monitoring of viral excretion.82 Critical" exact="disease" post="COVID-19 could be categorized as a critical disease if"/>
 <result pre="excretion.82 Critical disease COVID-19 could be categorized as a critical" exact="disease" post="if one or more of the following conditions have"/>
 <result pre="to 20 days which is dependent on the monitoring of" exact="viral" post="excretion. In some countries such as Switzerland, tocilizumab has"/>
 <result pre="and inotropic support.82 COVID-19 in patients with underlying diseases Cardiovascular" exact="disease" post="ACE2 has a critical role in cardiac and immune"/>
 <result pre="role in cardiac and immune systems. ACE2 is related to" exact="heart" post="function and it could be a potential cause of"/>
 <result pre="heart function and it could be a potential cause of" exact="hypertension" post="and diabetes mellitus development.83 Since ACE2 is a functional"/>
 <result pre="and it could be a potential cause of hypertension and" exact="diabetes mellitus" post="development.83 Since ACE2 is a functional receptor for COVID-19,"/>
 <result pre="is a functional receptor for COVID-19, in patients with underlying" exact="cardiovascular" post="diseases, clinical symptoms of COVID-19 are more severe and"/>
 <result pre="more severe and fatal than the general population because, in" exact="cardiovascular" post="diseases, ACE2 secretion might be enhanced. Administration of renin-angiotensin-aldosterone"/>
 <result pre="of administration of these drugs in COVID-19 patients with underlying" exact="cardiovascular disease," post="hypertension, and diabetes mellitus is still controversial and further"/>
 <result pre="drugs in COVID-19 patients with underlying cardiovascular disease, hypertension, and" exact="diabetes mellitus" post="is still controversial and further studies are required for"/>
 <result pre="would be suitable alternative of these drugs in patients with" exact="cardiovascular disease" post="who are infected with COVID-19.83 The previous meta-analysis revealed"/>
 <result pre="be suitable alternative of these drugs in patients with cardiovascular" exact="disease" post="who are infected with COVID-19.83 The previous meta-analysis revealed"/>
 <result pre="infected with COVID-19.83 The previous meta-analysis revealed that patients with" exact="cardiovascular" post="diseases are more likely prone to MERS-CoV infection. Also,"/>
 <result pre="recent studies showed that elderly group with comorbidities such as" exact="coronary heart disease," post="hypertension, and diabetes mellitus are more prone to COVID-19"/>
 <result pre="studies showed that elderly group with comorbidities such as coronary" exact="heart" post="disease, hypertension, and diabetes mellitus are more prone to"/>
 <result pre="group with comorbidities such as coronary heart disease, hypertension, and" exact="diabetes mellitus" post="are more prone to COVID-19 infection86 and in these"/>
 <result pre="infection86 and in these patients, COVID-19 could induce more severe" exact="systemic" post="symptoms and more severe pneumonia and a large number"/>
 <result pre="COVID-19 could induce more severe systemic symptoms and more severe" exact="pneumonia" post="and a large number of COVID-19 deaths were associated"/>
 <result pre="and a large number of COVID-19 deaths were associated with" exact="cardiovascular" post="diseases. COVID-19 infection could act as a precipitating factor"/>
 <result pre="number of COVID-19 deaths were associated with cardiovascular diseases. COVID-19" exact="infection" post="could act as a precipitating factor in patients with"/>
 <result pre="could act as a precipitating factor in patients with the" exact="acute" post="coronary syndrome (ACS), in which necrosis and myocardial ischemia"/>
 <result pre="as a precipitating factor in patients with the acute coronary" exact="syndrome" post="(ACS), in which necrosis and myocardial ischemia have occurred."/>
 <result pre="with the acute coronary syndrome (ACS), in which necrosis and" exact="myocardial ischemia" post="have occurred. In cases with ACS, COVID-19 infection could"/>
 <result pre="the acute coronary syndrome (ACS), in which necrosis and myocardial" exact="ischemia" post="have occurred. In cases with ACS, COVID-19 infection could"/>
 <result pre="and myocardial ischemia have occurred. In cases with ACS, COVID-19" exact="infection" post="could deteriorate patientsâ€™ condition and lead to death. Coronary"/>
 <result pre="infection could deteriorate patientsâ€™ condition and lead to death. Coronary" exact="heart" post="disease is related to COVID-19-induced acute cardiac events and"/>
 <result pre="could deteriorate patientsâ€™ condition and lead to death. Coronary heart" exact="disease" post="is related to COVID-19-induced acute cardiac events and these"/>
 <result pre="lead to death. Coronary heart disease is related to COVID-19-induced" exact="acute" post="cardiac events and these patients are poor prognosis after"/>
 <result pre="poor prognosis after COVID-19 infection. In general, new-onset or worsening" exact="heart" post="failure, new-onset or worsening arrhythmia, and myocardial infarction would"/>
 <result pre="new-onset or worsening heart failure, new-onset or worsening arrhythmia, and" exact="myocardial infarction" post="would be common features of patients with pneumonia such"/>
 <result pre="and myocardial infarction would be common features of patients with" exact="pneumonia" post="such as COVID-19.86 So cardiovascular protection with suitable pharmacotherapy"/>
 <result pre="common features of patients with pneumonia such as COVID-19.86 So" exact="cardiovascular" post="protection with suitable pharmacotherapy options is essential in COVID-19"/>
 <result pre="suitable pharmacotherapy options is essential in COVID-19 patients with underlying" exact="cardiovascular" post="diseases.84,85 As a hypothesis, it seems that ACEIs could"/>
 <result pre="As a hypothesis, it seems that ACEIs could precipitate COVID-19" exact="pneumonia" post="but ARBs, through blockade of angiotensin receptors, may have"/>
 <result pre="of angiotensin receptors, may have beneficial effects in these patients." exact="Kidney" post="disease Most of the hepatic metabolites of drugs considered"/>
 <result pre="angiotensin receptors, may have beneficial effects in these patients. Kidney" exact="disease" post="Most of the hepatic metabolites of drugs considered in"/>
 <result pre="in urine due to renal elimination. So in patients with" exact="chronic" post="kidney disease (CKD), the accumulation of drug metabolites would"/>
 <result pre="urine due to renal elimination. So in patients with chronic" exact="kidney disease" post="(CKD), the accumulation of drug metabolites would be expected"/>
 <result pre="due to renal elimination. So in patients with chronic kidney" exact="disease" post="(CKD), the accumulation of drug metabolites would be expected"/>
 <result pre="as mentioned above.87 A small study on COVID-19 patients with" exact="end-stage renal disease" post="(ESRD) who undergone hemodialysis, revealed that the number of"/>
 <result pre="mentioned above.87 A small study on COVID-19 patients with end-stage" exact="renal disease" post="(ESRD) who undergone hemodialysis, revealed that the number of"/>
 <result pre="above.87 A small study on COVID-19 patients with end-stage renal" exact="disease" post="(ESRD) who undergone hemodialysis, revealed that the number of"/>
 <result pre="disease (ESRD) who undergone hemodialysis, revealed that the number of" exact="total" post="T cells (cytotoxic and helper T cells), natural killer"/>
 <result pre="cells), natural killer (NK) cells, and inflammatory cytokines were significantly" exact="lower" post="than these levels in non-hemodialysis patients with COVID-19. This"/>
 <result pre="but further studies are required to confirm this hypothesis.66 Liver" exact="disease" post="According to the recent studies, liver abnormalities (such as"/>
 <result pre="and ALT serum levels) have been occurred after and during" exact="infection" post="with COVID-19. These abnormalities would be related to viral"/>
 <result pre="during infection with COVID-19. These abnormalities would be related to" exact="viral infection" post="pathogenesis and direct liver injury or it may be"/>
 <result pre="infection with COVID-19. These abnormalities would be related to viral" exact="infection" post="pathogenesis and direct liver injury or it may be"/>
 <result pre="hepatic metabolism. So injury to the liver because of pre-existing" exact="liver disease" post="or acute hepatic failure would impair drug metabolism and"/>
 <result pre="metabolism. So injury to the liver because of pre-existing liver" exact="disease" post="or acute hepatic failure would impair drug metabolism and"/>
 <result pre="injury to the liver because of pre-existing liver disease or" exact="acute" post="hepatic failure would impair drug metabolism and therefore drug"/>
 <result pre="the patientsâ€™ liver function as mentioned above. The impact of" exact="chronic" post="liver diseases such as chronic viral hepatitis, alcoholic and"/>
 <result pre="mentioned above. The impact of chronic liver diseases such as" exact="chronic" post="viral hepatitis, alcoholic and non-alcoholic liver diseases on occurrence"/>
 <result pre="above. The impact of chronic liver diseases such as chronic" exact="viral hepatitis," post="alcoholic and non-alcoholic liver diseases on occurrence of liver"/>
 <result pre="impact of chronic liver diseases such as chronic viral hepatitis," exact="alcoholic" post="and non-alcoholic liver diseases on occurrence of liver injury"/>
 <result pre="chronic viral hepatitis, alcoholic and non-alcoholic liver diseases on occurrence" exact="of liver" post="injury related to COVID-19 infection, still is not clear."/>
 <result pre="is not clear. It seems that in patients with underlying" exact="liver disease," post="with the immunocompromised condition, who infected with COVID-19, more"/>
 <result pre="Wuhan city of China in December 2019. Soon this coronavirus" exact="disease" post="2019 (COVID-19) spreads around the world and became a"/>
 <result pre="discussed in detail. Also, challenges in the pharmacotherapy of COVID-19" exact="pneumonia" post="in patients with underlying disease especially heart diseases have"/>
 <result pre="in the pharmacotherapy of COVID-19 pneumonia in patients with underlying" exact="disease" post="especially heart diseases have been considered based on pharmacokinetic"/>
 <result pre="pharmacotherapy of COVID-19 pneumonia in patients with underlying disease especially" exact="heart" post="diseases have been considered based on pharmacokinetic and pharmacodynamic"/>
 <result pre="drugs. Patients with COVID-19 who have cardiac diseases such as" exact="coronary heart disease" post="and those who are ACEIs consumers should be highly"/>
 <result pre="Patients with COVID-19 who have cardiac diseases such as coronary" exact="heart" post="disease and those who are ACEIs consumers should be"/>
 <result pre="with COVID-19 who have cardiac diseases such as coronary heart" exact="disease" post="and those who are ACEIs consumers should be highly"/>
 <result pre="highly considered in treatment options. Also, patients with liver and" exact="kidney disease" post="and those with organ transplants should be considered to"/>
 <result pre="considered in treatment options. Also, patients with liver and kidney" exact="disease" post="and those with organ transplants should be considered to"/>
 <result pre="common coldJAMA3238202070770831971553 2GuoYRCaoQDHongZSTanYYChenSDJinHJThe origin, transmission and clinical therapies on coronavirus" exact="disease" post="2019 (COVID-19) outbreak - an update on the statusMil"/>
 <result pre="J Epidemiol2020 5WuZMcGooganJM.Characteristics of and important lessons from the coronavirus" exact="disease" post="2019 (COVID-19) outbreak in China: summary of a report"/>
 <result pre="report of 72 314 cases from the Chinese Center for" exact="Disease" post="Control and PreventionJAMA2020 6SohrabiCAlsafiZO'NeillNKhanMKerwanAAl-JabirAWorld Health Organization declares global emergency:"/>
 <result pre="review of the 2019 novel coronavirus (COVID-19)Int J Surg762020717632112977 7LivingstonEBucherK.Coronavirus" exact="disease" post="2019 (COVID-19) in ItalyJAMA2020 8FilatovASharmaPHindiFEspinosaPSNeurological complications of coronavirus disease"/>
 <result pre="7LivingstonEBucherK.Coronavirus disease 2019 (COVID-19) in ItalyJAMA2020 8FilatovASharmaPHindiFEspinosaPSNeurological complications of coronavirus" exact="disease" post="(COVID-19): encephalopathyCureus1232020 9GhasemiyehPBorhani-HaghighiAKarimzadehIMohammadi-SamaniSVazinASafariAMajor neurologic adverse drug reactions, potential drugâ€&quot;drug"/>
 <result pre="and clinical characteristics of 99 cases of 2019 novel coronavirus" exact="pneumonia" post="in Wuhan, China: a descriptive studyThe Lancet395102232020507513 11GuJHanBWangJCOVID-19: Gastrointestinal"/>
 <result pre="and potential fecal-oral transmissionGastroenterology2020 12RothanHAByrareddySN.The epidemiology and pathogenesis of coronavirus" exact="disease" post="(COVID-19) outbreakJ Autoimmun2020102433 13WangTDuZZhuFCaoZAnYGaoYComorbidities and multi-organ injuries in the"/>
 <result pre="treatment of COVID-19The Lancet395102282020e52 14XuZShiLWangYZhangJHuangLZhangCPathological findings of COVID-19 associated with" exact="acute" post="respiratory distress syndromeLancet Resp Med2020 15SahinAR.Novel coronavirus (COVID-19) outbreak:"/>
 <result pre="of COVID-19The Lancet395102282020e52 14XuZShiLWangYZhangJHuangLZhangCPathological findings of COVID-19 associated with acute" exact="respiratory" post="distress syndromeLancet Resp Med2020 15SahinAR.Novel coronavirus (COVID-19) outbreak: A"/>
 <result pre="transmission of COVID-19JAMA2020 18ShiHHanXJiangNCaoYAlwalidOGuJRadiological findings from 81 patients with COVID-19" exact="pneumonia" post="in Wuhan, China: a descriptive studyLancet Infect Dis204202042543432105637 19BernheimAMeiXHuangMYangYFayadZAZhangNChest"/>
 <result pre="(COVID-19): relationship to duration of infectionRadiology2020200463 20GuanWJNiZYHuYLiangWHOuCQHeJXClinical characteristics of coronavirus" exact="disease" post="2019 in ChinaN Engl J Med2020 21LanLXuDYeGXiaCWangSLiYPositive RT-PCR test"/>
 <result pre="results in patients recovered from COVID-19JAMA2020 22OrganizationWH.Laboratory testing for coronavirus" exact="disease" post="2019 (COVID-19) in suspected human cases: interim guidance, 2"/>
 <result pre="novel coronavirus-important information for cliniciansJAMA.2020 25DongLHuSGaoJDiscovering drugs to treat coronavirus" exact="disease" post="2019 (COVID-19)Drug Discov Ther1412020586032147628 26BelhadiDPeiffer-SmadjaNLescureF-XYazdanpanahYMentrÃ©FLaouÃ©nanCA brief review of antiviral"/>
 <result pre="27WangYZhuLQ.Pharmaceutical care recommendations for antiviral treatments in children with coronavirus" exact="disease" post="2019World J Pediatr2020 28Al-TawfiqJAAl-HomoudAHMemishZARemdesivir as a possible therapeutic option"/>
 <result pre="(GS-5734â&quot;¢)2020US Food and Drug AdministrationSilver Spring, MD 30ZhangCWuZLiJ-WZhaoHWangG-QThe cytokine release" exact="syndrome" post="(CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist"/>
 <result pre="a recommendation to examine the effect of hydroxychloroquine in preventing" exact="infection" post="and progressionJ Antimicrob Chemother2020 39ColsonPRolainJMLagierJCBrouquiPRaoultDChloroquine and hydroxychloroquine as available"/>
 <result pre="phosphate has shown apparent efficacy in treatment of COVID-19 associated" exact="pneumonia" post="in clinical studiesBiosci Trends1412020727332074550 42GautretPLagierJ-CParolaPMeddebLMailheMDoudierBHydroxychloroquine and azithromycin as a"/>
 <result pre="J Antimicrob Agents2020105949 43SchluenzLARamos-OteroGPNawarskasJJChloroquine or hydroxychloroquine for management of coronavirus" exact="disease" post="2019: friend or Foe?Cardiol Rev285202026627132769401 44HernandezAVRomanYMPasupuletiVBarbozaJJWhiteCMHydroxychloroquine or chloroquine for"/>
 <result pre="vitroCell Res303202026927132020029 50DavoodiL, JafarpourH, KazeminejadA, SoleymaniE, AkbariZ, RazaviA. Hydroxychloroquine-Induced Stevens-Johnson" exact="Syndrome" post="in COVID-19: A rare Case Report. 2020. 51SharmaANMesinkovskaNAParavarTCharacterizing the"/>
 <result pre="in pregnancy and lactation: a reference guide to fetal and" exact="neonatal" post="risk2012Lippincott Williams &amp;amp; Wilkins 54BoriskinYLenevaIPecheurE-IPolyakSArbidol: a broad-spectrum antiviral compound"/>
 <result pre="Williams &amp;amp; Wilkins 54BoriskinYLenevaIPecheurE-IPolyakSArbidol: a broad-spectrum antiviral compound that blocks" exact="viral" post="fusionCurr Med Chem15102008997100518393857 55BlaisingJPolyakSJPÃ©cheurE-IArbidol as a broad-spectrum antiviral: an"/>
 <result pre="lethal mutagenesis?J Mol Med8022002869511907645 58TodMFarcy-AfifMStoccoJBoyerNBoutonVSinegreMPharmacokinetic/pharmacodynamic and time-to-event models of ribavirin-induced" exact="anaemia" post="in chronic hepatitis CClin Pharmacokinet444200541742815828854 59ChenFChanKJiangYKaoRLuHFanKIn vitro susceptibility of"/>
 <result pre="Mol Med8022002869511907645 58TodMFarcy-AfifMStoccoJBoyerNBoutonVSinegreMPharmacokinetic/pharmacodynamic and time-to-event models of ribavirin-induced anaemia in" exact="chronic hepatitis" post="CClin Pharmacokinet444200541742815828854 59ChenFChanKJiangYKaoRLuHFanKIn vitro susceptibility of 10 clinical isolates"/>
 <result pre="Med8022002869511907645 58TodMFarcy-AfifMStoccoJBoyerNBoutonVSinegreMPharmacokinetic/pharmacodynamic and time-to-event models of ribavirin-induced anaemia in chronic" exact="hepatitis" post="CClin Pharmacokinet444200541742815828854 59ChenFChanKJiangYKaoRLuHFanKIn vitro susceptibility of 10 clinical isolates"/>
 <result pre="Combination therapy with lopinavir/ritonavir, ribavirin and interferon-Î± for Middle East" exact="respiratory" post="syndromeAntiviral Therapy21201645545926492219 61CaoBWangYWenDLiuWWangJFanGA trial of lopinavir-ritonavir in adults hospitalized"/>
 <result pre="of the index patient who caused tertiary transmission of COVID-19" exact="infection" post="in Korea: the application of lopinavir/ritonavir for the treatment"/>
 <result pre="the application of lopinavir/ritonavir for the treatment of COVID-19 infected" exact="pneumonia" post="monitored by quantitative RT-PCRJ Korean Med Sci3562020e7932056407 63CvetkovicRSGoaKL.Lopinavir/ritonavirDrugs638200376980212662125 64LiuFXuAZhangYXuanWYanTPanKPatients"/>
 <result pre="angiotensin blockadeNephron202019 67CronRQChathamWW.The rheumatologist's role in COVID-19J Rheumatol2020 68FavalliEGIngegnoliFDe LuciaOCincinelliGCimazRCaporaliRCOVID-19" exact="infection" post="and rheumatoid arthritis: Faraway, so close!Autoimmun Rev2020102523 69XuXHanMLiTSunWWangDFuBEffective treatment"/>
 <result pre="and functional exhaustion of T cells in patients with coronavirus" exact="disease" post="2019 (COVID-19)Medrxiv2020 71LiGDe ClercqETherapeutic options for the 2019 novel"/>
 <result pre="plasma therapy in severe COVID-19 patients: a pilot studymedRxiv2020 78SarvepalliD.Coronavirus" exact="disease" post="2019: a comprehensive review of etiology, pathogenesis, diagnosis, and"/>
 <result pre="of extracorporeal membrane oxygenationJAMA2020 82Available from: https://epidemio.wiv-isp.be/ID/Documents/Covid19/COVID-19_InterimGuidelines_Treatment_ENG.pdf. 83FangLKarakiulakisGRothMAre patients with" exact="hypertension" post="and diabetes mellitus at increased risk for COVID-19 infection?Lancet"/>
 <result pre="membrane oxygenationJAMA2020 82Available from: https://epidemio.wiv-isp.be/ID/Documents/Covid19/COVID-19_InterimGuidelines_Treatment_ENG.pdf. 83FangLKarakiulakisGRothMAre patients with hypertension and" exact="diabetes mellitus" post="at increased risk for COVID-19 infection?Lancet Resp Med2020 84ZhengYYMaYTZhangJYXieXCOVID-19"/>
 <result pre="increased risk for COVID-19 infection?Lancet Resp Med2020 84ZhengYYMaYTZhangJYXieXCOVID-19 and the" exact="cardiovascular" post="systemNat Rev Cardiol2020 85ClerkinKJFriedJARaikhelkarJSayerGGriffinJMMasoumiACoronavirus disease 2019 (COVID-19) and cardiovascular"/>
 <result pre="Resp Med2020 84ZhengYYMaYTZhangJYXieXCOVID-19 and the cardiovascular systemNat Rev Cardiol2020 85ClerkinKJFriedJARaikhelkarJSayerGGriffinJMMasoumiACoronavirus" exact="disease" post="2019 (COVID-19) and cardiovascular diseaseCirculation2020 86ZhouFYuTDuRFanGLiuYLiuZClinical course and risk"/>
 <result pre="the cardiovascular systemNat Rev Cardiol2020 85ClerkinKJFriedJARaikhelkarJSayerGGriffinJMMasoumiACoronavirus disease 2019 (COVID-19) and" exact="cardiovascular" post="diseaseCirculation2020 86ZhouFYuTDuRFanGLiuYLiuZClinical course and risk factors for mortality of"/>
 <result pre="cardiovascular diseaseCirculation2020 86ZhouFYuTDuRFanGLiuYLiuZClinical course and risk factors for mortality of" exact="adult" post="inpatients with COVID-19 in Wuhan, China: a retrospective cohort"/>
</results>
